Micro-RNAs targeting the estrogen receptor alpha involved in endocrine therapy resistance in breast cancer

被引：0
|
作者：
Marquez-Mendoza, J. M. [2 ]
Baranda-Avila, N. [1 ]
Lizano, M. [1 ,3 ]
Langley, E. [1 ]
机构：
[1] Inst Nacl Cancerol, Unidad Invest Biomed Canc, Subdirecc Invest Bas, Mexico City 14080, Mexico
[2] Univ Nacl Autonoma Mexico, Programa Doctorado Ciencias Biomed, Inst Invest Biomed, Ciudad Univ, Mexico City 04510, Mexico
[3] Univ Nacl Autonoma Mexico, Dept Med Genom & Toxicol Ambiental, Inst Invest Biomed, Ciudad Univ, Mexico City 04510, Mexico
来源：
BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR BASIS OF DISEASE | 2025年 / 1871卷 / 05期
关键词：
Noncoding RNAs; micro-RNAs; Estrogen receptor alpha; Endocrine therapy resistance; Breast cancer; ENHANCES TAMOXIFEN RESISTANCE; ER-ALPHA; GENE-EXPRESSION; TRANSCRIPTIONAL REGULATION; DIFFERENTIAL EXPRESSION; ANTIESTROGEN RESISTANCE; PROTEIN EXPRESSION; MIR-221; PROMOTES; DRUG-RESISTANCE; DOWN-REGULATION;
D O I：
10.1016/j.bbadis.2025.167783
中图分类号：
Q5 [生物化学]; Q7 [分子生物学];
学科分类号：
071010 ; 081704 ;
摘要：
Endocrine therapy resistance (ETR) in breast cancer (BC) is a multicausal phenomenon with diverse alterations in the tumor cell interactome. Within these alterations, non-coding RNAs (ncRNAs) such as micro-RNAs (miRNAs) modulate the expression of tumor suppressor genes and proto-oncogenes, such as the ESR1 gene encoding estrogen receptor alpha (ER alpha). This work aims to review the effects of miRNAs targeting ER alpha mRNA and their mechanisms related to ETR in BC. A thorough review of the literature and an in silico study were carried out to elucidate the involvement of each miRNA, thus contributing to the understanding of ETR in BC.
引用
收藏
页数：17
相关论文
共 50 条
  • [41] Endocrine Resistance in Hormone Receptor Positive Breast Cancer-From Mechanism to Therapy
    Rani, Aradhana
    Stebbing, Justin
    Giamas, Georgios
    Murphy, John
    FRONTIERS IN ENDOCRINOLOGY, 2019, 10
  • [42] Resistance to endocrine therapy in breast cancer
    Junichi Kurebayashi
    Cancer Chemotherapy and Pharmacology, 2005, 56 : 39 - 46
  • [43] Resistance to endocrine therapy in breast cancer
    Kurebayashi, J
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2005, 56 (Suppl 1) : S39 - S46
  • [44] Breast Cancer Chemoprevention: Targeting the Estrogen Receptor
    Chlebowski, Rowan T.
    Prabhaker, Radhika
    Tagawa, Tomoko
    AMERICAN JOURNAL OF HEMATOLOGY-ONCOLOGY, 2016, 12 (01) : 6 - 13
  • [45] The NF-KB pathway and endocrine therapy resistance in breast cancer
    Khongthong, Phungern
    Roseweir, Antonia K.
    Edwards, Joanne
    ENDOCRINE-RELATED CANCER, 2019, 26 (06) : R369 - R380
  • [46] Resistance to endocrine therapy in breast cancer: molecular mechanisms and future goals
    Szostakowska, Malgorzata
    Trebinska-Stryjewska, Alicja
    Grzybowska, Ewa Anna
    Fabisiewicz, Anna
    BREAST CANCER RESEARCH AND TREATMENT, 2019, 173 (03) : 489 - 497
  • [47] Nucleo-cytoplasmic transport of estrogen receptor alpha in breast cancer cells
    Tecalco-Cruz, Angeles C.
    Perez-Alvarado, Issis A.
    Ramirez-Jarquin, Josue O.
    Rocha-Zavaleta, Leticia
    CELLULAR SIGNALLING, 2017, 34 : 121 - 132
  • [48] ZBTB7A governs estrogen receptor alpha expression in breast cancer
    Molloy, Mary Ellen
    Lewinska, Monika
    Williamson, Amanda K.
    Thanh Thao Nguyen
    Kuser-Abali, Gamze
    Gong, Lu
    Yan, Jiawei
    Little, John B.
    Pandolfi, Pier Paolo
    Yuan, Zhi-Min
    JOURNAL OF MOLECULAR CELL BIOLOGY, 2018, 10 (04) : 273 - 284
  • [49] MicroRNA-497 downregulation contributes to cell proliferation, migration, and invasion of estrogen receptor alpha negative breast cancer by targeting estrogen-related receptor alpha
    Han, Li
    Liu, Bo
    Jiang, Lixi
    Liu, Junyan
    Han, Shumei
    TUMOR BIOLOGY, 2016, 37 (10) : 13205 - 13214
  • [50] Abbreviated endocrine therapy duration for low estrogen receptor-positive breast cancer: The counter to extended endocrine therapy
    Poterala, Johanna E.
    Wisinski, Kari B.
    CANCER, 2022, 128 (09) : 1724 - 1726
12345